Furthermore, docking studies revealed that acetylated compounds exhibited a stronger affinity for HER2 than for USP7, suggesting HER2 as the likely receptor target, given its presence alongside USP7 in the A2780 cancer cell line [55]. The gene discussed is ERBB2; the disease is cancer.